Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HWX0102
- Development stage
- Unknown
- Lead developer
- Jiangsu Kanion Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HWX0102 is an investigational small molecule drug candidate currently in Phase 1 clinical development for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Developed by Kanion Pharmaceutical in collaboration with Huawe Medicine, the asset is part of a pipeline of innovative chemical drugs (Class 1). While the specific molecular target and mechanism of action have not been publicly disclosed, the program has been identified for potential development in international markets, including the United States. The development phase is approximated based on visual pipeline progress indicators provided by the sponsor.
- Other names
- HWX0102HWX-0102HWX 0102
Beyond the preview
Go deeper on HWX0102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HWX0102.